{"doi":"10.3390/geriatrics7010013","title":"A Randomized, Open-Label Study to Assess Efficacy of Weekly Assumption of Cholecalciferol versus Calcifediol in Older Patients with Hypovitaminosis D","abstract":"<jats:p>The aim of this single-center, open-label, randomized controlled study was to evaluate which formulation of vitamin D—between cholecalciferol and calcifediol—is most effective in the treatment of hypovitaminosis D in older adults. Demographic characteristics, clinical history, and comprehensive geriatric assessment were recorded at admission. Eligible patients were randomly assigned an equivalent vitamin D supplement, either with cholecalciferol or calcifediol, from the time of hospital admission to three months after discharge. Among the 140 older patients included (mean age 83 ± 6.6 years, 57.8% females), 69 received cholecalciferol and 71 received calcifediol. The mean plasma values of 25-hydroxyvitamin D3 (25OH-vitamin D3) found at the time of enrollment were 16.8 ± 9.9 ng/mL in patients receiving cholecalciferol and 18.8 ± 13.3 ng/mL in those treated with calcifediol (p = 0.31). At the three month follow-up, the mean concentration of 25OH-vitamin D3 was significantly higher in patients treated with calcifediol than in those receiving cholecalciferol (30.7 ± 8.4 vs. 45.4 ± 9.8 ng/mL, respectively; p &lt; 0.001). Supplementation with either cholecalciferol or calcifediol effectively results in reaching the optimal circulating values of 25OH-vitamin D3 in older patients suffering from hypovitaminosis D. However, supplementation with calcifediol led to average circulating values of 25OH-vitamin D3 that were significantly higher (over 50%) than those obtained with cholecalciferol.</jats:p>","journal":"Geriatrics","year":2022,"id":589026,"datarank":0.6157096135633466,"base_score":2.3978952727983707,"endowment":2.3978952727983707,"self_citation_contribution":0.3596842909197557,"citation_network_contribution":0.2560253226435909,"self_endowment_contribution":0.3596842909197557,"citer_contribution":0.2560253226435909,"corpus_percentile":null,"corpus_rank":null,"citation_count":10,"citer_count":10,"citers_with_citation_signal":10,"citers_with_endowment":10,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":654843,"name":"Valeria Calsolaro","orcid":"0000-0001-6446-5251","position":1,"is_corresponding":false},{"id":209868,"name":"Filippo Niccolai","orcid":null,"position":2,"is_corresponding":false},{"id":209869,"name":"Alessia Maria Calabrese","orcid":null,"position":3,"is_corresponding":false},{"id":209870,"name":"Riccardo Franchi","orcid":null,"position":4,"is_corresponding":false},{"id":209871,"name":"Sara Rogani","orcid":null,"position":5,"is_corresponding":false},{"id":209872,"name":"Giulia Coppini","orcid":null,"position":6,"is_corresponding":false},{"id":209873,"name":"Virginia Morelli","orcid":null,"position":7,"is_corresponding":false},{"id":209874,"name":"Nadia Caraccio","orcid":null,"position":8,"is_corresponding":false},{"id":209875,"name":"Fabio Monzani","orcid":"0000-0003-1676-098X","position":9,"is_corresponding":false},{"id":209866,"name":"Chukwuma Okoye","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"A Randomized, Open-Label Study to Assess Efficacy of Weekly Assumption of Cholecalciferol versus Calcifediol in Older Patients with Hypovitaminosis D","abstract":"<jats:p>The aim of this single-center, open-label, randomized controlled study was to evaluate which formulation of vitamin D—between cholecalciferol and calcifediol—is most effective in the treatment of hypovitaminosis D in older adults. Demographic characteristics, clinical history, and comprehensive geriatric assessment were recorded at admission. Eligible patients were randomly assigned an equivalent vitamin D supplement, either with cholecalciferol or calcifediol, from the time of hospital admission to three months after discharge. Among the 140 older patients included (mean age 83 ± 6.6 years, 57.8% females), 69 received cholecalciferol and 71 received calcifediol. The mean plasma values of 25-hydroxyvitamin D3 (25OH-vitamin D3) found at the time of enrollment were 16.8 ± 9.9 ng/mL in patients receiving cholecalciferol and 18.8 ± 13.3 ng/mL in those treated with calcifediol (p = 0.31). At the three month follow-up, the mean concentration of 25OH-vitamin D3 was significantly higher in patients treated with calcifediol than in those receiving cholecalciferol (30.7 ± 8.4 vs. 45.4 ± 9.8 ng/mL, respectively; p &lt; 0.001). Supplementation with either cholecalciferol or calcifediol effectively results in reaching the optimal circulating values of 25OH-vitamin D3 in older patients suffering from hypovitaminosis D. However, supplementation with calcifediol led to average circulating values of 25OH-vitamin D3 that were significantly higher (over 50%) than those obtained with cholecalciferol.</jats:p>","is_dataset_classified":null,"base_score":2.3978952727983707,"endowment":2.3978952727983707,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"35076537","pmcid":"PMC8788272","openalex_id":"https://openalex.org/W4226065757","authors":[],"funders":[],"total_grants":0,"fwci":1.3623,"citation_percentile":0.80087641,"influential_citations":0,"citation_trend":[{"year":2022,"count":3},{"year":2023,"count":6},{"year":2025,"count":1}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.mdpi.com/2308-3417/7/1/13/pdf?version=1641534411","host_type":"journal"},{"url":"https://www.mdpi.com/2308-3417/7/1/13/pdf?version=1641534411","host_type":"publisher"},{"url":"https://www.mdpi.com/2308-3417/7/1/13/pdf","host_type":"publisher"},{"url":"https://doi.org/10.3390/geriatrics7010013","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/35076537","host_type":"repository"},{"url":"http://hdl.handle.net/11568/1145096","host_type":"repository"},{"url":"https://hdl.handle.net/10281/418037","host_type":"repository"},{"url":"https://doaj.org/article/ec1ced430ec54f27b08a26fa2bc52b56","host_type":"repository"},{"url":"https://dx.doi.org/10.3390/geriatrics7010013","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/8788272","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC8788272","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC8788272?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Vitamin D Research Studies","Parathyroid Disorders and Treatments","Pharmacological Effects and Toxicity Studies"],"mesh_terms":[],"keywords":["Calcifediol","Cholecalciferol","Medicine","Vitamin D and neurology","Internal medicine","Hypovitaminosis","Quality of Life Research","Vitamin","vitamin D deficiency","Gastroenterology","Endocrinology","Pathology","Public health","Vitamin D","Hypovitaminosis D","Older Patient"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-23T11:58:24.164824Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}